From the helm: Proteomics International (ASX:PIQ), Dr. Richard Lipscombe, Managing Director

Bell Direct
July 7, 2025

In this episode of From the helm, Bell Financial Group’s Grady Wulff speaks with Proteomics International Laboratories (ASX: PIQ) CEO, Dr. Richard Lipscombe, about the company’s ground breaking work in predictive diagnostics and the global opportunity for its world-first blood tests.

In this video, Dr. Lipscombe covers:
·      (0:47): An overview of PIQ and its FY26 goals
·      (1:38): The significance of three world-first blood tests
·      (5:26): The global addressable markets for these conditions
·      (6:25): Clinical trial progress and commercialisation roadmap
·      (8:14): How the diagnostic tests work and deliver value to patients
·      (9:16): Commercialisation strategy across key regions
·      (11:23): Additional assets in the PIQ pipeline
·      (12:36): What investors can expect over the next 12 months

Note: This interview was recorded on 3 July 2025.

Morning Bell 12 February

Bell Direct
February 12, 2025

Morning Bell 11 February

Bell Direct
February 11, 2025

Morning Bell 10 February

Bell Direct
February 10, 2025

Weekly Wrap 7 February

Bell Direct
February 7, 2025

Morning Bell 6 February

Bell Direct
February 6, 2025

Morning Bell 5 February

Bell Direct
February 5, 2025

Morning Bell 4 February

Bell Direct
February 4, 2025

Morning Bell 3 February

Bell Direct
February 3, 2025

Weekly Wrap 31 January

Bell Direct
January 31, 2025

Morning Bell 30 January

Bell Direct
January 30, 2025